A Health Economic Evaluation of Sleepio at a Fortune 500 Company

Sleepio users had 28% lower health care costs compared to matched controls.

A Fortune 500 company, in conjunction with IBM Watson Health, conducted an economic evaluation to test whether our flagship digital therapeutic for insomnia, Sleepio, would lower health care costs for their employees.

Individuals who used Sleepio had 28% lower annualized total healthcare costs compared to those who did not use Sleepio — demonstrating $1,677 lower health care costs per employee that used Sleepio.

A peek inside:

Read the white paper
Share article